Chemistry:ADSB-FUB-187
From HandWiki
Short description: Synthetic cannabinoid
 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C26H31ClFN5O4S |
| Molar mass | 564.07 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
ADSB-FUB-187 is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB1 receptor with a binding affinity of Ki = 0.09 nM and an EC50 of 1.09 nM.[1] It was originally developed by Pfizer in 2009, being example 187 from patent WO 2009/106982. While it is the most tightly binding compound from this patent in terms of Ki, it is not the most potent compound at producing a CB1 mediated pharmacological effect, with at least 17 other compounds from the patent having lower EC50 values.[2]
Legality
Sweden's public health agency suggested classifying ADSB-FUB-187 as hazardous substance on November 10, 2014, following its use as an ingredient in grey-market synthetic cannabis products.[3]
See also
References
- ↑ "The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonist New Psychoactive Substances: Evolution". New Psychoactive Substances. Handbook of Experimental Pharmacology. 252. 2018. pp. 191–226. doi:10.1007/164_2018_144. ISBN 978-3-030-10560-0.
- ↑ Buchler IP, Hayes MJ, Hedge SG, Landis S, Hockerman SL, Jones DE, Kortum SW, Rico JG, Tenbrink RE, Wu KW, "Indazole derivatives", WO patent 2009106982, published 3 September 2009, assigned to Pfizer Inc..
- ↑ "Cannabinoider föreslås bli klassade som hälsofarlig vara" (in sv). Folkhälsomyndigheten (The Swedish Public Health Agency). http://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2014/november/cannabinoider-foreslas-bli-klassade-som-halsofarlig-vara/.
 |  |
